In clinical practice, PA is primarily used to treat copper metabolism disorders and is a key medication for managing conditions such as Wilson’s disease (WD), exerting systemic effects through high-affinity binding to non-ceruloplasmin-bound copper in the plasma (35, 36). The gene discussed is CP; the disease is disorder of copper metabolism.